Contributions
Abstract: P985
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Introduction: This study evaluates the significance of the blood neutrophil-to-lymphocyte ratio (NLR) in the different courses of multiple sclerosis (MS); relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and optic neuritis (ON). The NLR is measured in relation to relapse and remission and Expanded Disability Status Scale (EDSS).
Methods: A total of 382 patients suffering from RRMS (n=138), SPMS (n=30), PPMS (n=55), CIS (n=19) or ON (n=140) and 813 healthy controls (HC) were included. Exclusion criteria: active infections, active or chronic inflammatory diseases, autoimmune diseases, pregnancy, present malignancy and surgery, immunosuppressant or disease modifying therapies, and steroids. Complete blood count, demographic, and clinical data from MS patients were evaluated retrospectively. The NLRs were calculated and compared for all participants by student's t-test and adjusted for age, gender, EDSS and disease duration. Logistic regression models were constructed for EDSS ≥ 4,0 as outcome and age, gender, NLR, and disease duration as predictor variables.
Results: The NLR was significant higher (p< 0.001) in MS and ON patients compared to HC. Patients in relapse had a significant higher NLR (p< 0.01) than patients in remission, but no difference in the CRP, ESR, and EDSS. SPMS and PPMS patients showed no significant difference in NLR. No difference was found between patients in the relapsing and progressive phase of MS. Neither NLR or any of the other predictor variables in our logistic regression model, significantly predicted an EDSS score of ≥4.0
Conclusion: MS and ON patients have a significantly higher NLR than HC, indicating the occurrence of chronic inflammation. NLR may be a marker of disease activity, because of the significantly higher NLR in patients with relapse compared to patients in remission. This needs confirmation in future trials.
Disclosure:
AK. Bisgaard: Nothing to disclose
G. Pihl-Jensen: Nothing to disclose
JL. Frederiksen: Nothing to disclose
Abstract: P985
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Introduction: This study evaluates the significance of the blood neutrophil-to-lymphocyte ratio (NLR) in the different courses of multiple sclerosis (MS); relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS) and optic neuritis (ON). The NLR is measured in relation to relapse and remission and Expanded Disability Status Scale (EDSS).
Methods: A total of 382 patients suffering from RRMS (n=138), SPMS (n=30), PPMS (n=55), CIS (n=19) or ON (n=140) and 813 healthy controls (HC) were included. Exclusion criteria: active infections, active or chronic inflammatory diseases, autoimmune diseases, pregnancy, present malignancy and surgery, immunosuppressant or disease modifying therapies, and steroids. Complete blood count, demographic, and clinical data from MS patients were evaluated retrospectively. The NLRs were calculated and compared for all participants by student's t-test and adjusted for age, gender, EDSS and disease duration. Logistic regression models were constructed for EDSS ≥ 4,0 as outcome and age, gender, NLR, and disease duration as predictor variables.
Results: The NLR was significant higher (p< 0.001) in MS and ON patients compared to HC. Patients in relapse had a significant higher NLR (p< 0.01) than patients in remission, but no difference in the CRP, ESR, and EDSS. SPMS and PPMS patients showed no significant difference in NLR. No difference was found between patients in the relapsing and progressive phase of MS. Neither NLR or any of the other predictor variables in our logistic regression model, significantly predicted an EDSS score of ≥4.0
Conclusion: MS and ON patients have a significantly higher NLR than HC, indicating the occurrence of chronic inflammation. NLR may be a marker of disease activity, because of the significantly higher NLR in patients with relapse compared to patients in remission. This needs confirmation in future trials.
Disclosure:
AK. Bisgaard: Nothing to disclose
G. Pihl-Jensen: Nothing to disclose
JL. Frederiksen: Nothing to disclose